CBD-V is under intense investigation in Epilepsy, Parkinson's, Multiple Sclerosis ,seizure, spasm and tremor


“Our research collaboration with GW over the last several years has shown that 'CBD and CBD-V' not only exerts significant anticonvulsant effects in a wide range of preclinical models of seizure and epilepsy, it is also better tolerated compared to existing anti-epileptic drugs.” - Dr. Ben Whalley, Senior Lecturer in Pharmacology at the Reading School of Pharmacy


  • What is CBD-V?

  • What is the difference between CBD and CBD-V

  • Is it toxic?

  • What are its effects?

  • Is there any research on CBD-V?

  • Is CBD-V legal?

  • What strains are high in CBD-V?

Cannabigerol - the mama of all cannabinoids






CBD-V differs from CBD only by the substitution of a pentyl for a propyl (3 carbon) sidechain, or for laymen and women, there are two less carbons on the molecule's tail.


CBD, the main non-psychoactive ingredient of marijuana has taken the world medical community by storm.  Used as a mixture in a high CBD strain,  alone or with some THC, patients are ditching their pain killers, anti-inflammatory drugs, opiates and other pharmaceutical preparations for CBD.  


"These unique pharmacological properties make cannabinoids exceedingly safe to use in both principle and practice." - 420 EOL


Why are people turning to CBD?  For the simple reason that it works much better its synthetic and is much, much less toxic.  Compare zero deaths from cannabis based medicines versus opiates, which are killing at the absolutely astounding rate of 50 people per 100,000 (and more) in many precincts.  


There is another type of CBD, called CBD-V, which has 3 less carbons in its molecular tail.  This small change in the molecule drastically affects its behavior with receptors that are involved in most every body system.  CBD for example, dials down pain, dials down and reduces tension on muscles that previously were ready to spasm at any moment.  


Doctor that Treated 20,000 Patients Explains You Body's Endocannabinoid System


Researchers know that an analogue of THC, called THC-V (less 3 carbons on the molecule tail), has wonderfully energising, yet tranquilizing effects, like the "Tom Brady" zone.  THC-V also suppresses appetite, a most desirable side effect that most of the population wants.  


“This patent is important as we believe that CBD-V has the potential to become an important new treatment option in the field of epilepsy.” - Justin Gover, CEO - GW - Major Pharma Corp.


So upfront, scientists know that CBD-V is very probably medicinal, it's very probably non-toxic, and that its likely to be similar but different to CBD in many respects.  Here is what we know right now about CBD-V, and you can be certain that the marijuana brainiacs out there are looking at breeding strains higher in this "exotic" cannabinoid.




Rather than being some kind of tip of the spear, high-tech cannabinoid, it turns out that CBD-V exists in quantity in feral populations of Indica and Sativa, particularly strains with genetics originating in the Himalaya region.  CBD-V is present in the old-school hashish used for centuries by yogis in their practice.  Of course, despite the centuries of use, big pharma and their militia, the DEA and FDA claim that this CBD-V is a dangerous narcotic, despite it being 100% non-psychoactive.  


Since the DEA decided to classify CBD as a Schedule I drug, as more dangerous than mega serial killer fentanyl - which is schedule II, the Feds have lost all credibility among law enforcement, the military, the marijuana industry and most certainly the parents of Epileptic children who use CBD to control or even stop their seizures all together.


Based on its Schedule I status in the United States, very little clinical research is available or will be available, into the near future from Yankee land. However, this is not the case in Canada and England, where CBD-V studies are being conducted at a high-level.



The Chinese are onto CBD-V.. Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy ...CN 103025325 A ...ABSTRACT...This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy.



Phyto Cannabinoids are a group of about 100 organic chemical compounds found in marijuana with medical efficacy - in addition to providing a "recreational high". First discovered in 1964 in Israel by noted researcher Dr. Mechoulam, cannabinoids have been found to work synergistically within the homo-sapien body via the endocannabinoid system.

Endocannabinoids are molecules produced by mammals to regulate nervous and bodily function.  Phytocannabinoids mimic the action of naturally occurring endocannabinoids.  Defects in the endocannabinoid system results in the failure to control muscles, nerves, psychological reactions like fear and stress among many other functions.  Cannabinoids work medically by normalizing receptor function, dialing down pain, fear, convulsions, etc.   A surplus of cannabinoids can result in a panic attack but effects are temporary and homeostasis returns in a few hours.  


Because CBD-V is a non-psychoactive cannabinoid, it is common in strains of cannabis that have only trace amounts of THC.  Strains with high CBD and CBD-V with low THC is desirable for many parents wanting to treat their children with an effective, non-toxic remedy.  In chronic and advanced conditions, CBD oil concentrate extracts afford heavy-duty relief, without debilitating the patient (getting them stoned).



Cannabigerol (CBG)

CBG – The Next Big Cannabinoid after CBD


CBD-V was shown to have anti-convulsant effects in animal studies and from patient testimonials.  This has sparked some well-financed, mature pharmaceutical operations to conduct clinical trials, especially in the study of Epilepsy.

This is anti-epilepsy activity is thought to be due to its action at TRPV1 receptors and the modulation of gene expression.  Preliminary research has inspired medical inquiries into CBD-V's efficacy in cancer, Crohn's disease, Parkinson's, to name but a few disorders.

Similarly to CBD, CBD-V is not scheduled by the Convention on Psychotropic Substances (in the UK).  CBD-V is being actively developed by GW Pharmaceuticals pursuant to its demonstrated neurochemical pathway for anti-epileptic and anti-convulsive action. GW is in phase 2 clinical  trials for adult epilepsy.  Trials are underway for a CBD-V product to be tested in children right now in Australia (2017).


"THC-V is more strongly psychoactive than THC, but only has about half the duration of THC."  


By looking at this relationship and the known cannabinoid chemistry, one expects that the duration of CBD-V to be similarly reduced.  In any case, oral dosing of CBD-V is expected to peak at about 3 or so hours after ingestion, with a medication cycle of perhaps 6 hours.


"CBD-V exerted significant anticonvulsant effects in 3 models of seizure that were not mediated by the CB1 cannabinoid receptor and were of comparable efficacy with purified CBD-V. These findings strongly support the further clinical development of CBD-V BDSs for the treatment of epilepsy."  - Br. J. Pharmacol. 2013


"These results indicate that CBD-V is an effective anti-convulsant in a broad range of seizure models. Also, it did not significantly affect normal motor function and this merits further investigation as a novel anti-epileptic in chronic epilepsy human models." - Br. J Pharmacol. 2012


“Our work in this area shows that CBD and CBD-V are well tolerated and exert significant anti-epileptiform, anti-seizure, and anti-epileptic effects in animal models.” - 2013 study by the University of Reading in London

CBD-V and THC-V may be effective treatments for vomiting and nausea, such as that suffered by cancer patients undergoing chemotherapy. The study’s authors said CBD-V may have therapeutic potential in reducing nausea.” - British Journal of Pharmacology 2013


The pharmacological properties of CBD lead us to believe that CBD-V might be efficacious in conditions like Crohn's and Cancer.

420Evaluations Online:  If you want to try CBD-V, you should first contact your favorite health care professional, especially one with experience in cannabis based medicines.  Strains with higher levels of CBD-V are uncommon, but it can be found in high CBD strains.  You must ask the supplier for a copy of the cannabinoid test profile and check the amount of CBD-V.  Therapeutic doses are thought to start at about 2-3% in the bud.  

In California and Nevada, a medical doctor's recommendation for marijuana is required to purchase medical cannabis from a dispensary, cannabis club, compassion service, cooperative or delivery service.  Fortunately, the process is easy and fast.  Just fill out a form that asks about your medical symptoms and conditions and press send.  Shortly thereafter, the doctor will review your file.  Patient's only pay, if they are approved.  We also provide Cannabis ID cards and cultivation permits.




Around The World, Researchers Begin Clinical Trials of Cannabis For Epilepsy

While a large body of anecdotal and laboratory evidence points to cannabis as an effective treatment for epilepsy, research in humans is just beginning to catch up.

Source of Cannabinoids close up

Top 5 Cannabinoids - What are They? What do they Do?

On Wednesday, GW Pharmaceuticals – the UK-based company behind the natural cannabis spray Sativex – announced the start of the first round of clinical trials of a new cannabis treatment for epilepsy.

In the press release, Dr. Stephen Wright, Director of Research and Development at GW, said the company has spent years testing cannabis in pre-clinical models – which include cell cultures and animals.


Cannabidivarin-rich Cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.

Epilepsy is the most prevalent neurological disease and is characterized by recurrent seizures. Here, we investigate the anticonvulsant profiles of cannabis-derived botanical drug substances - BDSs - rich in cannabidivarin - CBD-V - and containing cannabidiol  - CBD - in acute in-vivo seizure models and the binding of CBD-V BDSs and their components at CB1 receptors.


Cannabidivarin is anticonvulsant in mice and rats.

Phyto-cannabinoids in Cannabis Sativa have several diverse pharmacological targets extending well beyond cannabinoid receptors and several exert significant anticonvulsant effects. For the first time, the anticonvulsant profile of the phytocannabinoid cannabidivarin (CBD-V) in vitro and in in vivo seizure models was investigated.

These results indicate that CBD-V is an effective anti-convulsant in a broad range of seizure modalities. Also it did not significantly affect normal motor function and, therefore, merits further investigation as a novel anti-epileptic in chronic epilepsy models.


The anti-convulsant profiles of CBD-V were evaluated in 3 animal models for acute seizure. Purified CBD-V and CBD were evaluated in an isobolographic study for pharmacological interactions. CBD-V-BDS effects on motor-function were investigated using static-beam and grip-strength assaying.


Study: Cannabidivarin (CBD-V) Can Help Treat Epileptic Seizures  

By now It’s no secret that several chemical compounds found in medical marijuana can assist in the treatment of epilepsy. GW Pharmaceuticals, a well funded pharmaceutical company has already commenced clinical trials to test several of marijuana's components for efficacy...


Medical Marijuana: Much More Than Just THC and CBD

For years now delta-9Ttetrahydrocannabinol or commonly known as  THC was the most popular and widely researched cannabinoid in cannabis based medical science. But, these days it appears that cannabidiol offers even greater medical benefit, without psychoactivity.


Study: Cannabinoids Show Potential In Reducing Nausea  

THC-V, CBD-V might reduce nausea In humans, but many of the benefits of cannabis still go unreported, cannabis has become a relatively common treatment for nausea events.





Interesting Posts